These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. Bardia A; Jhaveri K; Kalinsky K; Pernas S; Tsurutani J; Xu B; Hamilton E; Im SA; Nowecki Z; Sohn J; Laurentiis M; Jañez NM; Adamo B; Lee KS; Jung KH; Rubovszky G; Tseng LM; Lu YS; Yuan Y; Maxwell MJ; Haddad V; Khan SS; Rugo HS; Pistilli B Future Oncol; 2024 Mar; 20(8):423-436. PubMed ID: 37387213 [TBL] [Abstract][Full Text] [Related]
3. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Bardia A; Pusztai L; Albain K; Ciruelos EM; Im SA; Hershman D; Kalinsky K; Isaacs C; Loirat D; Testa L; Tokunaga E; Wu J; Dry H; Barlow W; Kozarski R; Maxwell M; Harbeck N; Sharma P Ther Adv Med Oncol; 2024; 16():17588359241248336. PubMed ID: 38686016 [TBL] [Abstract][Full Text] [Related]
4. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Bardia A; Krop IE; Kogawa T; Juric D; Tolcher AW; Hamilton EP; Mukohara T; Lisberg A; Shimizu T; Spira AI; Tsurutani J; Damodaran S; Papadopoulos KP; Greenberg J; Kobayashi F; Zebger-Gong H; Wong R; Kawasaki Y; Nakamura T; Meric-Bernstam F J Clin Oncol; 2024 Jul; 42(19):2281-2294. PubMed ID: 38652877 [TBL] [Abstract][Full Text] [Related]
5. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Levy BP; Felip E; Reck M; Yang JC; Cappuzzo F; Yoneshima Y; Zhou C; Rawat S; Xie J; Basak P; Xu L; Sands J Future Oncol; 2023 Jul; 19(21):1461-1472. PubMed ID: 37249038 [TBL] [Abstract][Full Text] [Related]
6. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. Bardia A; Jhaveri K; Im SA; Pernas S; De Laurentiis M; Wang S; Martínez Jañez N; Borges G; Cescon DW; Hattori M; Lu YS; Hamilton E; Zhang Q; Tsurutani J; Kalinsky K; Rubini Liedke PE; Xu L; Fairhurst RM; Khan S; Denduluri N; Rugo HS; Xu B; Pistilli B; J Clin Oncol; 2024 Sep; ():JCO2400920. PubMed ID: 39265124 [TBL] [Abstract][Full Text] [Related]
7. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Heist RS; Sands J; Bardia A; Shimizu T; Lisberg A; Krop I; Yamamoto N; Kogawa T; Al-Hashimi S; Fung SSM; Galor A; Pisetzky F; Basak P; Lau C; Meric-Bernstam F Cancer Treat Rev; 2024 Apr; 125():102720. PubMed ID: 38502995 [TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer. Shastry M; Jacob S; Rugo HS; Hamilton E Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269 [TBL] [Abstract][Full Text] [Related]
9. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Okajima D; Yasuda S; Maejima T; Karibe T; Sakurai K; Aida T; Toki T; Yamaguchi J; Kitamura M; Kamei R; Fujitani T; Honda T; Shibutani T; Muramatsu S; Nakada T; Goto R; Takahashi S; Yamaguchi M; Hamada H; Noguchi Y; Murakami M; Abe Y; Agatsuma T Mol Cancer Ther; 2021 Dec; 20(12):2329-2340. PubMed ID: 34413126 [TBL] [Abstract][Full Text] [Related]